Viking Therapeutics (NASDAQ: VKTX)
You’re reading a free stock page from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More
Viking Therapeutics Return vs. S&P
|1 Year||5 Year||5 Year Annualized||Since IPO|
Viking Therapeutics Company Info
Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of therapies for metabolic and endocrine disorders. The company was founded by Brian Lian and Michael A. Dinerman on September 24, 2012 and is headquartered in San Diego, CA.
News & Analysis
Is it too late to buy shares of Viking Therapeutics?
Positive analyst coverage is fueling another uptick in the biotech's stock today.
Recent moves to the upside could be the beginning of a much larger bull run.
The biotech's shares can't escape the broader downward trend among its peer group today.
The biotech's midstage NASH candidate passed another key hurdle.
The biotech's shares dipped along with the broader markets in early-morning trading today.
The biotech's shares rose briefly this morning following a sizable price target revision by an investing firm.
The clinical-stage stock nearly doubled in price.
VKTX earnings call for the period ending June 30, 2022.
VKTX earnings call for the period ending March 31, 2022.
VKTX earnings call for the period ending December 31, 2021.
VKTX earnings call for the period ending September 30, 2021.
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.